Tags

Type your tag names separated by a space and hit enter

Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections.
Clin Infect Dis 2002; 34(11):1481-90CI

Abstract

Linezolid, the first available member of a new antibiotic class, the oxazolidinones, is broadly active against gram-positive bacteria, including drug-resistant strains. In this randomized, open-label trial, hospitalized adults with known or suspected methicillin-resistant Staphylococcus aureus (MRSA) infections were treated with linezolid (600 mg twice daily; n=240) or vancomycin (1 g twice daily; n=220) for 7-28 days. S. aureus was isolated from 53% of patients; 93% of these isolates were MRSA. Skin and soft-tissue infection was the most common diagnosis, followed by pneumonia and urinary tract infection. At the test-of-cure visit (15-21 days after the end of therapy), among evaluable patients with MRSA, there was no statistical difference between the 2 treatment groups with respect to clinical cure rates (73.2% of patients in the linezolid group and 73.1% in the vancomycin group) or microbiological success rates (58.9% in the linezolid group and 63.2% in the vancomycin group). Both regimens were well tolerated, with similar rates of adverse events.

Authors+Show Affiliations

Infectious Diseases Section, Veterans Administration Medical Center, Boise, ID, 83702, USA. dlsteven@mindspring.comNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

12015695

Citation

Stevens, Dennis L., et al. "Linezolid Versus Vancomycin for the Treatment of Methicillin-resistant Staphylococcus Aureus Infections." Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America, vol. 34, no. 11, 2002, pp. 1481-90.
Stevens DL, Herr D, Lampiris H, et al. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis. 2002;34(11):1481-90.
Stevens, D. L., Herr, D., Lampiris, H., Hunt, J. L., Batts, D. H., & Hafkin, B. (2002). Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America, 34(11), pp. 1481-90.
Stevens DL, et al. Linezolid Versus Vancomycin for the Treatment of Methicillin-resistant Staphylococcus Aureus Infections. Clin Infect Dis. 2002 Jun 1;34(11):1481-90. PubMed PMID: 12015695.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. AU - Stevens,Dennis L, AU - Herr,Daniel, AU - Lampiris,Harry, AU - Hunt,John Lee, AU - Batts,Donald H, AU - Hafkin,Barry, Y1 - 2002/05/13/ PY - 2001/08/13/received PY - 2002/01/15/revised PY - 2002/5/17/pubmed PY - 2002/5/22/medline PY - 2002/5/17/entrez SP - 1481 EP - 90 JF - Clinical infectious diseases : an official publication of the Infectious Diseases Society of America JO - Clin. Infect. Dis. VL - 34 IS - 11 N2 - Linezolid, the first available member of a new antibiotic class, the oxazolidinones, is broadly active against gram-positive bacteria, including drug-resistant strains. In this randomized, open-label trial, hospitalized adults with known or suspected methicillin-resistant Staphylococcus aureus (MRSA) infections were treated with linezolid (600 mg twice daily; n=240) or vancomycin (1 g twice daily; n=220) for 7-28 days. S. aureus was isolated from 53% of patients; 93% of these isolates were MRSA. Skin and soft-tissue infection was the most common diagnosis, followed by pneumonia and urinary tract infection. At the test-of-cure visit (15-21 days after the end of therapy), among evaluable patients with MRSA, there was no statistical difference between the 2 treatment groups with respect to clinical cure rates (73.2% of patients in the linezolid group and 73.1% in the vancomycin group) or microbiological success rates (58.9% in the linezolid group and 63.2% in the vancomycin group). Both regimens were well tolerated, with similar rates of adverse events. SN - 1537-6591 UR - https://www.unboundmedicine.com/medline/citation/12015695/Linezolid_versus_vancomycin_for_the_treatment_of_methicillin_resistant_Staphylococcus_aureus_infections_ L2 - https://academic.oup.com/cid/article-lookup/doi/10.1086/340353 DB - PRIME DP - Unbound Medicine ER -